Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innovate (VATE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Innovate (VATE) over the last 17 years, with Q3 2025 value amounting to $35.5 million.

  • Innovate's Cash & Equivalents fell 3039.22% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 3039.22%. This contributed to the annual value of $48.8 million for FY2024, which is 3960.4% down from last year.
  • As of Q3 2025, Innovate's Cash & Equivalents stood at $35.5 million, which was down 3039.22% from $33.4 million recorded in Q2 2025.
  • In the past 5 years, Innovate's Cash & Equivalents registered a high of $80.8 million during Q4 2023, and its lowest value of $16.6 million during Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $38.4 million (2024), whereas its average is $43.9 million.
  • In the last 5 years, Innovate's Cash & Equivalents soared by 26375.84% in 2021 and then tumbled by 5835.41% in 2025.
  • Innovate's Cash & Equivalents (Quarter) stood at $45.5 million in 2021, then surged by 76.7% to $80.4 million in 2022, then increased by 0.5% to $80.8 million in 2023, then plummeted by 39.6% to $48.8 million in 2024, then dropped by 27.25% to $35.5 million in 2025.
  • Its Cash & Equivalents stands at $35.5 million for Q3 2025, versus $33.4 million for Q2 2025 and $33.3 million for Q1 2025.